T1	Participants 103 144	locally advanced resectable rectal cancer
T2	Participants 363 721	Patients with stage II/III LARC received capecitabine 1250 mg/m(2) twice daily for 2 weeks followed by intravenous cetuximab 400 mg/m(2) at week 3, then weekly intravenous 250 mg/m(2) cetuximab plus CRT including capecitabine 825 mg/m(2) twice daily (including weekends during radiotherapy) with radiotherapy of 45 Gy (25 x 1.8 Gy), 5 days a week for 5 weeks
T3	Participants 723 800	Total mesorectal excision was scheduled 4-6 weeks following completion of CRT
T4	Participants 1687 1716	patients with resectable LARC
